Supercharged immune cells take on tough pancreatic cancer

NCT ID NCT06828328

Recruiting now Disease control Sponsor: Shanghai Juncell Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 06, 2026 · Updated 3 times

Summary

This early-phase trial tests a new therapy called GC203 TIL, which uses a patient's own immune cells that are genetically modified to better attack pancreatic cancer. Ten adults whose cancer has not responded to standard treatments will receive these cells after a short course of chemotherapy. The main goal is to check safety, but researchers will also watch for tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gene-edited tumor infiltrating lymphocytes (GC203 TIL)
What this could lead to: If it works, this could point toward a new treatment option for advanced pancreatic cancer that has not responded to standard therapies.
What could go wrong: This is a very early, small trial (10 people) focused on safety, not proof of effectiveness. The treatment involves strong chemotherapy beforehand and may cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCRATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCRATIC DUCTAL ADENOCARCINOMA PANCREATIC CANCER TREATMENT SIDE EFFECTS TUMOR INFILTRATING LYMPHOCYTES

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Ruijin Hospital
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.